Associação entre os transcritos do gene BCR-ABL e o perfil hematológico laboratorial
Conteúdo do artigo principal
Resumo
Objetivo: Neste estudo, descrevemos os parâmetros hematológicos associados com os transcritos do gene BCR-ABL em pacientes com leucemia mieloide crônica (LMC). Métodos: Revisamos os resultados de 100 pacientes detectáveis para um dos transcritos do geneBCR-ABL. Os critérios de elegibilidade foram baseados na presença de um dos transcritos leucêmicos (b2a2, b3a2 e b2a2/b3a2), dados epidemiológicos e hematológicos completos. Os dados foram obtidos do sistema informatizado LABMASTER. O teste Kruskal-Wallis foi utilizado para comparar as medianas, das variáveis quantitativas, entre os transcritos do gene BCR-ABL e o teste qui-quadrado para comparar as variáveis qualitativas, adotando-se o p-valor com nível de significância menor ou igual a 0,05.Resultados: Quarenta e cinco pacientes (45%) apresentaram o transcrito b2a2, 24 (24%) o transcrito b3a2 e 31 (31%) uma coexpressão de b2a2/b3a2. Os indivíduos que expressaram o transcrito b3a2 apresentaram maior contagem de leucócitos e níveis de plaquetas, porém não encontramos diferenças, quando comparados com indivíduos que expressaram o outro transcrito. Conclusão: Concluímos que os transcritos do gene BCR-ABL não têm influência sobre os parâmetros hematológicos de pacientes com LMC nesse estudo.
Detalhes do artigo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Os autores mantêm os direitos autorais e concedem à Health Sciences Journal o direito de primeira publicação. A partir de 2024, as publicações serão licenciadas sob a Attribution 4.0 International , permitindo seu compartilhamento, reconhecendo a autoria e publicação inicial nesta revista.
Os autores estão autorizados a assumir contratos adicionais separadamente para distribuição não exclusiva da versão do trabalho publicada nesta revista (por exemplo, publicação em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
Os autores são incentivados a publicar e distribuir seu trabalho on-line (por exemplo, em repositórios institucionais ou em sua página pessoal) a qualquer momento após o processo editorial.
Além disso, o AUTOR fica informado e consente que a Health Sciences Journal possa incorporar seu artigo em bases de dados e indexadores científicos existentes ou futuros, nas condições definidas por estes a cada momento, o que envolverá, pelo menos, a possibilidade de que os titulares de esses bancos de dados podem executar as seguintes ações no artigo.
Referências
2. Neves WB, Brito AM, Vasconcelos AP, Melo FCBC, Melo RAM. Incidence and spatial distribution of Chronic Myeloid Leukemia by regions of economic development in the state of Pernambuco, Brazil. Hematol Transfus Cell Ther. 2019;41(3):212-5. https://doi.org/10.1016/j.htct.2018.08.009
3. Halon K, Copland M. Chronic myeloid leukemia. Medicine. 2017;45(5):287-91. https://doi.org/10.1016/j.mpmed.2017.02.004
4. Bávaro L, Martelli M, Cavo M, Soverini S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in Chronic Myeloid Leukemia: an update. Int J Mol Sci. 2019;20(24):6141. https://doi.org/10.3390/ijms20246141
5. Bennour A, Ouahchi I, Achour B, Zaier M, Youssef YB, Khelif A, et al. Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. Med Oncol. 2012;30(1):348. https://doi.org/10.1007/s12032-012-0348-z
6. Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019;33(5):1173-83. https://doi.org/10.1038/s41375-018-0341-4
7. Gaspar JC, Santana LS, Souza CMF, Caseiro MM, Giuliani RRS, Souza CB. Clonagem molecular do oncogene EZH2 de leucemia mieloide crônica e perspectivas terapêuticas. Mundo Saúde. 2015;39(3):307-15. https://doi.org/10.15343/0104-7809.20153903307315
8. Piedimonte M, Otone T, Afonso V, Ferrari A, Conte E, Divona M, et al. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. BMC Cancer. 2019;19(1):50. https://doi.org/10.1186/s12885-019-5265-5
9. Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS, et al. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Pediatr Oncol. 2014;35(1):26-30. https://doi.org/10.4103/0971-5851.133707
10. Al-Achkar W, Moassas F, Youssef N, Wafa A. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. J BUON. 2016;21(2):444-9. PMid:27273956
11. Almeida-Filho TP, Maia-Filho PA, Barbosa MC, Dutra LLA, Castro MF, Duarte FB, et al. Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? Hematol Transfus Cell Ther. 2019;41(2):114-8. https://doi.org/10.1016/j.htct.2018.10.003
12. Ayatollahi H, Keramati MR, Shirdel A, Kooshyar MM, Raiszadeh M, Shakeri S, et al. BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran. Caspian J Intern Med. 2018;9(1):66-70. https://doi.org/10.22088/cjim.9.1.65
13. Khorard JS, Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26(29):4806-13. https://doi.org/10.1200/JCO.2008.16.9953
14. Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol. 2017;92(8):797-805. https://doi.org/10.1002/ajh.24774
15. Balatzenko G, Vundinti BR, Margarita G. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression. Hematol Rep. 2011;3(1):e3. https://doi.org/10.4081/hr.2011.e3
16. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MD, O'Brien S, Rios MS, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive Chronic Myelogenous Leukemia. Cancer. 1995;76(6):992-7. https://doi.org/10.1002/1097-0142(19950915)76:6<992::AID-CNCR2820760612>3.0.CO;2-L
17. Lin HX, Sjaarda J, Dyck J, Stringer R, Hillis C, Harvey M, et al. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. Eur J Haematol. 2015;96(4):360-6. https://doi.org/10.1111/ejh.12597
18. Sastre DA, Argarana CE, Heller VB, Gallo M, Fernandez EN, Rodrígues CM. An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders. Genet Mol Biol. 2007;30(3):520-3. https://doi.org/10.1590/S1415-47572007000400003
19. Paz-y-Miño C, Burgos R, Morillo AS, Santos JC, Fiallo BF, Leone PE. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America. Cancer Genet Cytogenet. 2002;1(1):65-67. https://doi.org/10.1016/S0165-4608(01)00515-5
20. Bonilla CAA, Torres JD, Muskus CE, Gaviria GR, Sierra JC, Sanchez MS, et al. Frecuencia de los transcriptos p190 BCR-ABL y p210 BCR-ABL en una población colombiana con leucemia mieloide crónica (LMC) usando RT-PCR cualitativa. Iatreia [Internet]. 2014 [cited 2022 Aug 22];27(4):398-409. Available from: https://bit.ly/3CqbU06
21. Khazaal MS, Hamdan FB, Al‐Mayah QS. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients. Mol Genet Genomic Med. 2019;7(8):e809. https://doi.org/10.1002/mgg3.809
22. Bortolheiro TC, Chiattone CS. Leucemia Mielóide Crônica: história natural e classificação. Rev Bras Hematol Hemoter. 2008;30(suppl 1):3-7. https://doi.org/10.1590/S1516-84842008000700003
23. Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 2009;89(3):241-7. https://doi.org/10.1007/s00277-009-0822-7
24. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL Fusion Transcripts in Iranian Patients with Chronic Myeloid Leukemia. Arch Iran Med. 2008;11(3):247-251. PMId:18426313
25. Thakur MK, Mani ST. Estradiol regulates APP mRNA alternative splicing in the mice brain cortex. Neurosci Lett. 2005;381(1-2):154-7. https://doi.org/10.1016/j.neulet.2005.02.014
26. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127(10):1269-75. https://doi.org/10.1182/blood-2015-10-674242
27. Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, Chandra S, Chaudhuri U, et al. Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol. 2006;81(11):845-9. https://doi.org/10.1002/ajh.20682
28. Arana-Trejo RM, Ruíz Sánchez E, Ignacio-Ibarra G, Báez de la Fuente E, Garces O, Gómez Morales E, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol. 2002;24(3):145-50. https://doi.org/10.1046/j.1365-2257.2002.00413.x
29. Pagnano KBB, Miranda EC, Delamain MT, Duarte GO, de Paula EV, Lorand-Metze I, et al. Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. Clin Lymphoma Myeloma Leuk. 2017;17(11):728-33. https://doi.org/10.1016/j.clml.2017.06.009
30. Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99(9):1441-7. https://doi.org/10.3324/haematol.2013.096537